X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is -0.2 In other words, the correlation coefficient of the other stoc
Looking for the breakout at 12.08 with a short term target of 14.11. Technical strong buy at stoxline.
OraSure Technologies, Inc. (OSUR) 45 cents, or 4%, to 11.83, on 1.4 million shares traded on Thursday. The next near-term target is 14.
Downside risk pretty much eliminated now that OSUR has seen target price reached the lower limits of 11.21. if you guys have questions you should ask aw-esomeSTOCKS. They often respond to my emails which is helpful.
Ok, sold 1/6th of my position at $11. 13-year gain annualizes to 1 percent. Next slug goes at $11.25. Been posting here long enough that maybe someone was interested.
The quarterly guidance also includes the after-tax impact of a $12.5 million litigation settlement recently announced by the Company.
What the heck. 1Q guidance includes $12.5MM settlemnt from ancestry. Therefore operating loss in Q!??
If so, why does osur run up so high?
Yee Ha, now that's what I'm talking about. Nice ride up on earnings, in for one week.
COULD BUY GBSN FOR .20 SAME BUSINESS WOULD BE A WIN WIN WIN PLEASE LOOK INTO!!!!! OSUR OBVIOUSLY KNOWS HOW TO RUN A BUSINESS
BETHLEHEM, Pa., Nov. 29, 2016 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (OSUR), a leader in point of care diagnostic tests and specimen collection devices, announced today that it will begin fulfilling a contract to supply a foreign government with $18 million of product, primarily to support a nationwide hepatitis C (HCV) testing and treatment program with the goal of eliminating HCV infection across the country by 2020.
The contract calls for the purchase of $16 million of OraQuick® HCV Rapid Antibody Tests and $2 million of OraQuick® Rapid HIV-1/2 Antibody Tests. This represents the largest supply contract for OraQuick® rapid tests in the Company’s history.
Undervalued- listen to ANALYST investor call-
OraSure Technologies, Inc. (OSUR) announced today that a study conducted by Human Longevity, Inc. (HLI) and published in the Journal Scientific Reports (Nature Publishing Group) on August 25, 2016 proposes the use of the OMNIgene•GUT microbiome sample collection and stabilization device sold by OraSure’s wholly-owned subsidiary, DNA Genotek Inc., in global microbiome studies. The published report can be found online at http://www.nature.com/articles/srep31731.
Singapore confirms locally transmitted Zika cases Aug 28 2016, 12:52 ET | By: Yoel Minkoff, SA News Editor [Contact this editor with comments or a news tip]
Singapore authorities have identified 41 Zika cases that were transmitted locally, and warned that they expect to find more.
The cases appear to be the largest single beachhead the virus has made in Asia in the current epidemic, which has also been detected in countries like Bangladesh, Malaysia and the Philippines.
On Thursday, China added the U.S. to a list of Zika-infected countries, worrying U.S. exporters, who fear they will be required to fumigate containers destined for Chinese ports.
US blood supply should be screened for Zika, FDA says
By Susan Scutti, CNN Updated 5:44 PM ET, Fri August 26, 2016 FDA: Screen all blood donations for Zika
(CNN)The Food and Drug Administration has recommended screening the entire US blood supply for the Zika virus, it announced today, noting that screening donated blood is already underway in Florida and Puerto Rico.
More than 60 cases of Zika virus reported in Georgia
The number of travel-related Zika virus cases is growing in Georgia.
OraSure Technologies, Inc. (NASDAQ:OSUR) Earns Consensus Buy Rating By Christian wheeler - August 25, 2016
OraSure Technologies, Inc. (NASDAQ:OSUR) up 11.21% for the past 5 days, is under coverage of 6 analysts who collectively assign a buy rating on stock. 4 of the brokerages firms have a buy or better rating; the 0 sells versus 0 underperforms. The 5 stock analysts who cover the stock have an average PT at $8.1, with individual targets in the range of $7.5 to $9. The shares ended last trade at $7.74, implying that Wall Street analysts see shares climbing about 4.65 per cent in 12 months’ time.